A new drug for an aggressive form of skin cancer has been approved by the FDA, and recommended for approval by the EMA. The therapy has caused a bit of a buzz because it’s the first of its kind in a drug class known as oncolytic immunotherapies; the drug – Imlygic (talimogene laherparepvec) – is a live oral herpes virus (herpex simplex virus-1) that has been genetically modified to selectively attack cancer cells without harming normal tissue.

Read the full article now Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be! Login Email Password Forgot your password? Keep me logged in Log in Or register now - it’s free and always will be! You will benefit from: Unlimited access to ALL articles

News, interviews & opinions from leading industry experts

Receive print (and PDF) copies of The Medicine Maker magazine Register Or Login via Social Media Twitter By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.